Document Detail


An evaluation of the pharmacokinetics and pharmacodynamics of ivabradine for the treatment of heart failure.
MedLine Citation:
PMID:  24377458     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
Introduction: Ivabradine is a new heart-rate-lowering drug; the aim of this review was to analyze its role in heart failure (HF). Areas covered: This systematic review on the role of ivabradine in HF is based on material searched and obtained through Pubmed and Medline up to September 2013. Expert opinion: Heart rate (HR) is a risk factor in patients with HF, and its reduction is considered an important goal of therapy. The BEAUTIFUL trial demonstrated the benefits of ivabradine on prognosis (only on ischemic endpoints) in patients with coronary artery disease (CAD) and left ventricular systolic dysfunction (LVSD) and HR ≥ 60 bpm. In the SHIFT trial, which enrolled patients with LVSD, HF and HR ≥ 70 bpm, ivabradine administration (on top of guideline-based therapy, including β-blockers [BB]) was associated with a reduction of cardiovascular death and hospitalizations for HF, but BB were underutilized. Further studies are needed to test the efficacy of ivabradine in CAD patients with high HR and to shed light on the comparison between ivabradine and a more aggressive therapy with higher doses of BB in HF patients.
Authors:
Gian Marco Rosa; Simone Ferrero; Paola Ghione; Alberto Valbusa; Claudio Brunelli
Related Documents :
1984898 - Diltiazem increases late-onset congestive heart failure in postinfarction patients with...
17113398 - Congestion in acute heart failure syndromes: an essential target of evaluation and trea...
8786618 - A chronic cardiomyopathy in feedlot cattle attributed to toxic levels of salinomycin in...
24703918 - Use of myocardial strain imaging by echocardiography for the early detection of cardiot...
15326978 - Cardiac resynchronization therapy: optimizing the device, optimizing the patient.
24433978 - Association between multilayer left ventricular rotational mechanics and the developmen...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2013-12-31
Journal Detail:
Title:  Expert opinion on drug metabolism & toxicology     Volume:  -     ISSN:  1744-7607     ISO Abbreviation:  Expert Opin Drug Metab Toxicol     Publication Date:  2013 Dec 
Date Detail:
Created Date:  2013-12-31     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101228422     Medline TA:  Expert Opin Drug Metab Toxicol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  R-? lipoic acid ?-cyclodextrin complex increases energy expenditure: A 4-month feeding study in mice...
Next Document:  A Multisite Examination of Sexual Violence Risk and Therapeutic Change.